Rapamycin Utility for secondary prevention of skin tumors in renal transplant recipients with recurrent squamous cell carcinoma. (Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular)

Trial Profile

Rapamycin Utility for secondary prevention of skin tumors in renal transplant recipients with recurrent squamous cell carcinoma. (Utilidad de la Rapamicina para la prevención secundaria de tumores cutáneos en trasplantados renales con recidiva de carcinoma espinocelular)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2012

At a glance

  • Drugs Sirolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection; Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TUMORAPA-N
  • Most Recent Events

    • 22 Aug 2012 New trial record
    • 26 Jul 2012 Primary endpoint 'Disease-occurrence-rate' has been met.
    • 26 Jul 2012 Primary endpoint 'Disease-free-survival-duration' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top